


# Human Clinical Trial

Evaluating the Safety and Efficacy of

## Glucolin-9

A Randomized, Double-Blind Placebo Controlled Study



**CONTACT INFORMATION:**

ISV ENTERPRICES, INC.

Support@isventerprices.com

CONFIDENTIAL INFORMATION

Any part or all of the information in this report may be unpublished material.

This report is to be treated as confidential, and restricted to its intended purpose. Should any portion of this material be desired for publication, authorization is to be obtained from

ISV ENTERPRICES, INC.

11/2016

## ABSTRACT

**Background:** People with diabetes are at high risk of cardiac complications, which are exacerbated by elevated blood pressure and dysfunctional sugar and fat metabolism. The aim of this study was to evaluate effects of an herbal supplement, Glucolin-9, on blood glucose levels, triglycerides, cholesterol, and blood pressure in subjects with chronic uncontrolled blood glucose.

**Methods:** We did a randomized prospective double-blinded study in 100 subjects (47 men and 53 women) with fasting blood glucose levels between 160 and 240 mg/dL. The participants were randomly assigned to oral Glucolin-9 at 6 tablets daily (n=50) or placebo (n=50) for 90 days. The endpoints included fasting blood glucose, body mass, oral glucose tolerance test, total cholesterol, HDL, triglycerides, glycosylated hemoglobin and blood pressure.

**Results:** All study participants completed the study. Glucolin-9 reduced HbA1c, blood glucose (fasting and after challenge), triglycerides, systolic and diastolic blood pressure, total cholesterol, and body mass over time. Mean fasting glucose was significantly decreased in subjects taking Glucolin-9 at 30, 60 and 90 days after baseline relative to those taking placebo. HbA1c mean change from baseline to 90 days was significantly decreased in subjects taking Glucolin-9. The Glucolin-9 mean serum glucose was significantly decreased relative to placebo at 30, 120 and 180 minutes after the challenge. Triglycerides mean changes from baseline were significantly decreased by Glucolin-9 at 30, 60 and 90 days. For total cholesterol, Glucolin-9 mean change from baseline to 90 days was significantly decreased relative to placebo. High and low density lipoproteins were not significantly affected. Systolic and diastolic blood pressure was significantly decreased at 60-90 days, and mean body mass was significantly decreased relative to placebo at 90 days.

**Conclusions:** This study demonstrated a reduction in the mean fasting blood sugar, blood pressure and body mass in subjects randomized to Glucolin-9. These findings suggest that Glucolin-9, an over-the-counter preparation, deserves further evaluation of its activity in larger clinical studies.

### Introduction

Based on the data from the 2010 National Diabetes Fact Sheet published by the American Diabetes Association, 23.6 million children and adults in the United States (7.8% of the population) have diabetes and 1.6 million new cases of diabetes are diagnosed in people aged 20 years and older each year (1). In 2003-2004, there were an estimated 5.7 million people with undiagnosed diabetes and 57 million in a pre-diabetes state in the United States (2). In the latter, blood glucose levels known as impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) are in the range of 100-125 mg/dL, while higher levels are associated type 2 diabetes mellitus, now increasingly recognized as an autoimmune-inflammatory disease (2). Notably, people with pre-diabetes are at increased risk of developing type 2 diabetes, a condition characterized by impaired insulin secretion from pancreatic Langerhans islands cells, increased hepatic glucose production and in consequence high blood glucose levels, and decreased use of glucose in muscle tissue. These defects are mainly responsible for the development and progression of type 2 diabetes (3). Furthermore, insulin resistance is associated with decreased rates of glycolysis, glycogenesis, lipogenesis, and protein synthesis. People with type 2 diabetes are also at high risk of fatal and non-fatal vascular events. In 2003-2004, 75% of adults with self-reported diabetes had elevated blood pressure of > 130/80 mm Hg or used 2 prescription medications for hypertension. Intensive control of glycemia decreases some vascular complications such as retinopathy and nephropathy (4).

Glucolin-9 is an herbal dietary supplement composed of biotin, chromium (picolinat), garcinia cambogia extract (50% hydroxycitric acid), gymnema sylvestre extract (25%), cinnamon extract (4:1), bitter melon extract (10:1), betaine HCL, berberine HCL 97%, fennugreek, cellulose, stearic acid, silicon dioxide, magnesium stearate, and hydroxypropyl methylcellulose.

Another recently completed study compared the activity of Glucolin-9 to that of three anti-diabetic drugs; Metformin, Actos (pioglitazone hydrochloride), and Byetta (exenatide) in an obese diabetic mouse model using BKS.Cg<sup>m</sup>+/+ Lepr<sup>ob</sup>/BomTac female mice fed either normal diet or high fat diet (HFD) +/- drugs. Glucolin-9's protection against organ damage was comparable to that of Byetta and better than Actos and Metformin in the animals on normal diet. The mean values of most inflammatory plasma biomarkers were elevated in high fat diet relative to normal diet. Biomarker means varied significantly by treatment group and diet. On normal diet, Glucolin-9 decreased levels of a number of pro-inflammatory cytokines, chemokines and growth

factors such as eotaxin, MCP-1, MCP-3, M-CSF, and increased anti-inflammatory cytokine IL-4 relative to untreated. Glucolin-9 treatment decreased G-CSF, GM-CSF, and TGF $\beta$  relative to untreated in high fat animals. Pyruvate kinase and AGE increased, while insulin was decreased in animals treated with Glucolin-9 relative to untreated on normal diet. Glucolin-9 demonstrated superior anti-inflammatory activity relative to the commonly used anti-diabetic drugs against a background of genetic obesity, supporting the contention that Glucolin-9 may be an effective intervention for type-2 diabetes (Hampshire et al., submitted).

The goal of this clinical study was to assess the efficacy of Glucolin-9 treatment in diabetic subjects with fasting blood glucose levels between 160 and 240 mg/dL and to evaluate effects of oral Glucolin-9 on clinical endpoints used in the routine evaluation of diabetic subjects. Safety data was not collected.

## **METHODS**

ISV Enterprises contracted the clinical study with a contract research organization, Fenestra Research Laboratories (Fenestra), Las Vegas, NV. Fenestra also conducted the tests as described below. In 2013-2014, Fenestra recruited 47 men and 53 women ages 23 to 50 (33 Black, 32 Caucasian, 25 Asian and 10 Hispanic) using participants recruited from a large diverse population of people living in or near the Las Vegas, NV area, with chronic uncontrolled blood glucose (people with fasting blood glucose levels between 160 mg/dL and 240 mg/dL with a mean of 197 mg/dL).

Excluded were subjects with a history of head trauma, serious diseases or illness diagnosed at this time, known moderate to severe renal insufficiency, recent history (<6 months prior to Visit 1) of myocardial infarction. Also excluded were those who regularly used oxygen therapy, those with known active tuberculosis, with treated basal cell carcinoma, history of cancer within the last 5 years, thoracotomy with pulmonary resection within 1 year prior to the trial, those in a pulmonary rehabilitation program or who completed a pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit 1), taking prescribed diuretic medications, cardiac stimulants, or any other prescribed or nonprescribed medication that might alter testing results, those taking opiate analgesics prescribed or otherwise obtained for any treatment reason including migraine treatment, or for recreation and history of drug addiction or alcohol addiction within six (5) months of this study period, females who were pregnant, lactating, or nursing or who may become pregnant during the course of the study, and those diagnosed as HIV positive, diagnosed with AIDS, or with any neuromuscular condition including CP, MS, ALS, or Huntington's Chorea. Also excluded were people with uncontrolled hypertension (e.g. BP > 140/90), or any condition not previously named that, in the opinion of Fenestra investigators or intake staff, would jeopardize safety or affect the validity of the results collected in this study. The study included females or males 18 years of age or older, who signed a written informed consent. To be eligible for inclusion, potential subjects were required to document blood sugar imbalance for a minimum of the previous consecutive 6 months of the screening visit at a frequency of at least twenty (20) times each month based on daily glucometer readings. Eligible participants were randomized into two groups of 50 participants. The study was double blinded. Compliance to inclusion and exclusion criteria was monitored and maintained through bi-weekly phone calls with Fenestra personnel and in-person office visits. All participants were instructed to contact their regular healthcare professional if they had any unusual or uncomfortable symptoms during the course of this study. All participants were instructed to make no changes to their daily activity or consumption of food or liquid relating to the amount, volume, or type consumed.

### **Procedures**

Participants in both treatment groups, Glucolin-9 and placebo (vegetarian tablet, magnesium citrate, silicon dioxide), were instructed to take two tablets three times daily, or three tablets two times daily if only two meals, approximately 15 minutes before meals. Participants were instructed to take product only if they ate a meal. Participants who met all inclusion criteria and none of the exclusion criteria at the first visit (day 0) and gave signed informed consent were then provided either the placebo or Glucolin 9 along with instructions describing daily dosing to follow for the duration of the study. Baseline measurements were made at day 1 (visit 2). Following screening (day 0), randomization, and signed informed consent, participants entered a 1-week baseline period. In that time, participants were asked to refrain from taking any unnecessary over-the-counter or prescription medications, or natural products that they were not already taking for the remainder of the study. Ibuprofen, acetaminophen, and aspirin were allowed.

11/2016

At the third and fourth visits (days 14 and 30) evaluations were performed following standard procedures and the inclusion and exclusion criteria were again reviewed with each participant on an individual basis. The fifth visit took place on day 60 and the sixth and final visit on day 90.

At the screen and prior to randomization, 14 of the participants reported mild headaches and "not feeling well". All 100 study participants were attempting to control their glucose levels with diet and exercise. Diet and exercise were not monitored during the study, but all participants were instructed to make no changes in their diet, activities, or water intake during the duration of the study at the screening and at subsequent visits.

### Tests

The tests briefly described below were performed by Fenestra using standard clinical procedures.

**Fasting Blood Glucose:** Approximately 7 mL of venous blood was collected from each participant at each blood draw and fasting blood glucose was measured.

**Body Mass:** Body mass (lbs) was recorded on all participants at all 6 visits using a monthly calibrated weight scale.

**Glucose Challenge:** Each participant's fasting blood glucose (FBG) level was measured at baseline (day 2). For the oral glucose tolerance test (OGTT), all participants were given a test tablet (half of the participants were given active product and half of the participants were given placebo), followed by a standard 75 g carbohydrate load drink. Blood plasma readings were taken at 30 minute, 120 minute, and 180 minute intervals.

**Total Cholesterol:** Participant's blood was taken after a 12-14 hour fasting period. Participants were asked to abstain from alcohol for at least 24 hours before 5-19 ml of arterial blood was drawn.

**Lipoproteins:** LDL levels were calculated by subtracting HDL readings plus one fifth of the triglycerides from the total cholesterol.  $LDL = Total\ cholesterol - (HDL + Triglycerides/5)$ .

**Triglycerides:** The blood test was performed on fasting (12-14 hour) participants. Participants were asked to abstain from any alcohol for 24 hours before the test. Five to 10 mL of venous blood was drawn from each participant at each test interval.

**Blood Pressure:** Blood pressure was taken by medical professionals with a minimum of 20 years experience using a sphygmomanometer and stethoscope. Blood pressure measurements were taken an average of three times after a minimum rest of at least 15 minutes.

**Hemoglobin A1c (HbA1c, Glycohemoglobin, Glycated hemoglobin,**

**Glycosylated hemoglobin):** Blood was drawn on Day 1 and Day 90. An arterial blood sample was obtained by inserting a needle into an artery of the participant's arm and a standard HbA1c vial of blood was collected by a healthcare professional.

### Statistical methods

Continuously distributed outcomes were summarized with the mean  $\pm$  one standard deviation. Treatment groups (Glucolin-9, Placebo) were contrasted on the mean of continuously distributed outcomes using repeated measures linear models of the outcome in terms of time, treatment group, and the time by treatment group interaction with an autoregressive order 1 autocorrelation matrix. All statistical testing was 2-sided with a significance level of 5%. R Version 2.11.1 (R Foundation) was used throughout; tables were created using SAS Version 9.2 for Windows (SAS Institute, Cary, NC).

### RESULTS

All participants completed the study; there were no missing data.

**Demographic Characteristics:** Treatment groups were similar with regard to the proportion male [Glucolin-9 22 (44%), Placebo 25 (50%)] and mean age (Glucolin-9  $43.5 \pm 12.7$ , Placebo  $45.8 \pm 10.8$ ,  $p=0.32$ ) and the percentage of subjects of the white race was significantly decreased among those randomized to Glucolin-9 (Glucolin-9 24 (48%), Placebo 37 (74%),  $p=0.01$ ); see Table 1.8

**Fasting Serum Glucose:** Treatment group fasting glucose means (ng/dL), shown in Table 1, were similar at baseline (Glucolin-9  $196.6 \pm 17.5$ , Placebo  $196.9 \pm 17.4$ ,  $p=0.93$ ) whereas the Glucolin-9 mean (14 days: Glucolin-9  $96.6 \pm 10.3$ , Placebo  $205.5 \pm 30.7$ ,  $p<0.001$ ; 30 days: Glucolin-9  $96.5 \pm 11.0$ , Placebo  $204.9 \pm 21.6$ ,  $p<0.001$ ; 60 days: Glucolin-9  $94.8 \pm 10.1$ , Placebo  $209.4 \pm 22.5$ ,  $p<0.001$ ; 90 days: Glucolin-9  $89.4 \pm 9.2$ , Placebo  $205.2 \pm 20.2$ ,  $p<0.001$ ) and mean changes from baseline (Glucolin-9  $107.2 \pm 14.5$ , Placebo  $8.3 \pm 14.8$ ,  $p<0.001$ ) were significantly decreased at 90 days.



**HbA1c (%):** Treatment group HbA1c (%) means (Table 1) were similar at baseline (Glucolin-9 7.7±0.5, Placebo 7.7±0.5; p=0.93) whereas the mean at 90 days (Glucolin-9 4.7±0.3, Placebo 8±0.6, p<0.001) and the mean change from baseline to 90 days (Glucolin-9 -3.0±0.5, Placebo 0.3±0.4, p<0.001) were significantly decreased in subjects taking Glucolin-9 .

At 90 days, no subject who received Glucolin-9 had an HbA1c above 5%. In contrast, at 90 days no subject who received Placebo had an HbA1c below 6.9%.

**Glucose Challenge Test (ng/dL):** The Glucolin-9 mean serum glucose (Table 1) was significantly decreased relative to placebo at 30, 120 and 180 minutes after the challenge (30 minutes: Glucolin-9 110.1±24.1, Placebo 205.1±18.5, p<0.001; 120 minutes: Glucolin-9 110.0±23.0, Placebo 221.9±14.6, p<0.001; 180 minutes: Glucolin-9 109.5±23.3, Placebo 225.8±12.6, p<0.001).

**Triglycerides:** Treatment group triglycerides means (mg/dl), see Table 1 and Figure 1, were similar at baseline (Glucolin-9 255.2±48.1, Placebo 254.5±46.5, p=0.95) whereas the Glucolin-9 mean (30 days: Glucolin-9 234.6±50.2, Placebo 259.3±45.4, p=0.01; 60 days: Glucolin-9 213.9±44.4, Placebo 269.6±48.1, p<0.001; 90 days: Glucolin-9 203.2±42.4, Placebo 271.3±48.3, p<0.001) and mean changes from baseline (90 days: Glucolin-9 -52.0±23.7, Placebo 16.8±28.6, p<0.001) were significantly decreased at 90 days.

**Total Cholesterol:** The Glucolin-9 mean Cholesterol (g/dL), see Table 1, was significantly increased at baseline relative to placebo (Glucolin-9: 338.5±96.9, Placebo: 301.3±89.4, p=0.01). The treatment group Cholesterol means did not differ significantly at 90 days (90 days: Glucolin-9 240.0±32.8, Placebo 261.2±29.2, p=0.13) whereas the Glucolin-9 mean change from baseline was significantly decreased relative to placebo (changes from baseline to 90 days: Glucolin-9 -98.5±110.0, Placebo -40.1±99.6, p=0.004).

**High Density Lipoproteins (HDL):** The Glucolin-9 mean HDL (g/dL), see Table 1, did not differ significantly from the placebo mean at baseline (Glucolin-9: 56.8±29.8, Placebo: 57.3±29.8, p=0.93) or at 90 days (90 days: Glucolin-9 47.7±9.3, Placebo 52.6±10.5, p=0.28; changes from baseline to 90 days: Glucolin-9 -9.0±33.6, Placebo -4.7±35.0, p=0.45).

**Low Density Lipoproteins (LDL):** The Glucolin-9 mean LDL (mg/dL), shown in Table 1, was significantly increased at baseline relative to placebo (Glucolin-9: 230.7±106.9, Placebo: 193.2±87.2, p=0.01) whereas the treatment group LDL means and mean changes in LDL did not differ significantly at 90 days (90 days: Glucolin-9 151.7±33.5, Placebo 154.4±30.3, p=0.86; changes from baseline to 90 days: Glucolin-9 -79.0±120.8, Placebo -38±94.9, p=0.11).

**Ratio Of Total Cholesterol To High Density Lipoproteins:** The Glucolin-9 mean ratio of total cholesterol to high density lipoproteins (Table 1) did not differ significantly from the placebo mean at baseline (Glucolin-9: 8.5±5.9, Placebo: 7.2±5.1, p=0.10) or at 90 days (90 days: Glucolin-9 5.3±1.5, Placebo 5.1±1.1, p=0.88).

**Ratio Of Low Density Lipoproteins To High Density Lipoproteins:** The Glucolin-9 mean ratio of total cholesterol to high density lipoproteins (Table 1) did not differ significantly from the placebo mean at baseline (Glucolin-9: 6.2±5.2, Placebo: 4.9±4.3, p=0.06) or at 90 days (90 days: Glucolin-9 3.4±1.3, Placebo 3.1±0.9, p=0.65). **Systolic Blood Pressure:** The Glucolin-9 systolic blood pressure mean (Table 1) was significantly increased relative to placebo at baseline (Baseline: Glucolin-9 10 171.3±19.9, Placebo 155.2±25.1, p<0.001), whereas the treatment group means were not significantly different at 30 and 60 days (30 days: Glucolin-9 157.9±25.9, Placebo 154.2±21.4, p=0.37; 60 days: Glucolin-9 149.7±16.3, Placebo 155.4±19.4, p=0.16) and the Glucolin-9 mean was significantly decreased at 90 days (90 days: Glucolin-9 142.9±14.6, Placebo 155.2±18.9, p=0.003). Analyses on changes from baseline showed significantly decreased mean changes from baseline to 90 (p<0.001) days in subjects randomized to Glucolin-9.

**Diastolic Blood Pressure:** Treatment group diastolic blood pressure means (mm Hg), see Table 1, were similar at baseline and at 30 days (Baseline: Glucolin-9 75.2±9.9, Placebo 76.0±8.7, p=0.55; 30 days: Glucolin-9 74.5±6.4, Placebo 75.5±6.9, p=0.44), whereas the Glucolin-9 mean was significantly decrease at 60 and 90 days (60 days: Glucolin-9 71.9±4.3, Placebo 76.7±5.7, p=0.001; 90 days: Glucolin-9 70.3±3.2, Placebo 76.6±5.2, p<0.001). The mean change from baseline to 90 days was significantly decreased in subjects randomized to Glucolin-9 (p<0.001).

**Body Mass:** The Glucolin-9 mean body mass (lb), see Table 1, was not significantly different from the placebo mean at baseline (Glucolin-9: 211.4±54.7, Placebo: 211.6±53.6, p=0.99). The treatment group weight means did not differ significantly at 90 days (90 days: Glucolin-9 202.1±54.0, Placebo 211.6±52.8, p=0.38) whereas the Glucolin-9 mean change from baseline was significantly decreased relative to placebo (changes from baseline to 90 days: Glucolin-9 -9.3±3.1, Placebo 0.0±2.9, p<0.001).

## Discussion

This study in subjects with pre-diabetes and diabetes demonstrated statistically significant effects of Glucolin-9 on fasting glucose level and the glucose challenge test, HbA1c, and blood pressure. Total cholesterol was decreased but LDL and HDL were not significantly affected. With respect to body mass, Glucolin-9 treatment group mean change from baseline was significantly decreased relative to placebo.

Based on the magnitude of clinical responses, Glucolin-9 compared favorably to standard therapeutics used in treatment of diabetes. Metformin is one of the oldest anti-diabetes drugs and was claimed to "lower the blood sugar to minimum physiological limit" in treated patients. Based on its favorable toxicity profile it was widely used but was approved by the U.S. Food and Drug Administration for type 2 diabetes in 1994 (6). Median HbA1c was 7.4% in the Metformin group compared with 8.0% in the conventional group, and intensive glucose control with Metformin decreased the risk of diabetes related endpoints in overweight diabetic patients, and was associated with less weight gain (6). Pioglitazone (Actos), a drug in the thiazolidinedione family, selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-) and modulates the transcription of insulin-responsive genes involved in the control of glucose and lipid metabolism (7). Actos significantly decreased fasting plasma glucose level from  $11.0 \pm 2.0$  mmol/liter to  $8.9 \pm 1.1$  mmol/liter with a significant improvement in the hemoglobin HbA1c level from  $9.2 \pm 1.8\%$  to  $8.3 \pm 1.5\%$  (11). Rosiglitazone, another thiazolidinedione oral antidiabetic agent, has been shown to significantly reduce HbA1c and fasting plasma glucose under different dosing regimens (8). Exenatide is a synthetic version of exendin-4, a hormone found in the saliva of the Gila monster. It displays biological properties similar to human glucagon-like peptide-1 through regulation of glucose metabolism and insulin secretion but its mechanism of action is still under study [2]. A 52-week treatment with exenatide reduced HbA1c by  $-0.8 \pm 0.1\%$  (9). At present, the management of type 2 diabetes focuses on glucose control through lowering of blood glucose and by extension HbA1c and other advanced glycation end products (3). In our opinion, these clinical endpoints are symptoms of disease, not disease mechanisms. Persistent high blood sugar in people is a problem; however, even with perfect glucose control people still suffer from significant organ pathologies, morbidity and mortality. Drugs that are designed to control blood sugar have many liabilities such as induction of hypoglycemia. Thus the commonly accepted emphasis on controlling blood sugar as a sole endpoint may be somewhat misguided in that blood sugar level is only one of the multiple facets of diabetes. We feel that more emphasis should be placed on control of the immune dysfunction that is a major biochemical driver of the pathology of diabetes. Therefore, understanding how drugs impact inflammatory biomarker profiles will be extremely important in understanding and treating diabetes. We propose that the optimal therapeutic strategy for diabetes should address not only blood sugar control, but also be directed to control of immune system imbalance in an effort to delay disease progression (3). Given that type 2 diabetes is fundamentally an inflammatory disease (2), in our recent in vivo study in a model of human type 2 diabetes in obese mice, we selected a broad range of endpoints to evaluate mechanism of action of Glucolin-9. In addition to commonly tested metabolites (glucose, advanced glycation end product, insulin, cholesterol, triglycerides), we included pyruvate kinase, hexokinase II, and citrate as potentially relevant endpoints along with a large panel of cytokines, chemokines, endocrine markers and growth factors and have shown that Glucolin-9 significantly downregulated several pro-inflammatory chemokines, cytokines, and growth factors and upregulated levels of the anti-inflammatory cytokine IL-4. We speculate that Glucolin-9 may break the self-reinforcing inflammatory cycle and thus slow down the natural course of the disease (Hampshire *et al.*, submitted). In conclusion, this study demonstrated a reduction in the mean fasting blood sugar, blood pressure and body mass in subjects randomized to Glucolin-9. These findings suggest that Glucolin-9, an over-the-counter preparation, deserves further evaluation of its activity in larger clinical studies.

# Competing interests

---

Owners & consultants of ISV Enterprises Inc.

2016-11-16

## Authors' contributions

KRH, SM, and RM funded the study and analysis of the clinical data.

JM and CL performed statistical analysis of the clinical data.

EI, JM and RTS reviewed the results and wrote the manuscript.

## References

1. Steinbrook, R. Facing the diabetes epidemic--mandatory reporting of glycosylated hemoglobin values in New York City, *N Engl J Med* 2006;354(6):545-548.
2. Kohn, L.D., Wallace, B., Schwartz, F., and McCall, K. (2005) Is type 2 diabetes an autoimmune-inflammatory disorder of the innate immune system?, *Endocrinology* 2005;146(10):4192-4199.
3. DeFronzo, R. A. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going, *Am J Med* 2013;123(3 suppl):S38-48.
4. Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefebvre, P. J., Murray, G. D., Standl, E., Wilcox, R. G., Wilhelmsen, L., Betteridge, J., Birkeland, K., Golay, A., Heine, R. J., Koranyi, L., Laakso, M., Mokan, M., Norkus, A., Pirags, V., Podar, T., Scheen, A., Scherbaum, W., Schernthaner, G., Schmitz, O., Skrha, J., Smith, U., and Taton, J. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomised controlled trial, *Lancet* 2005;366(9493):1279-1289.
5. <http://diabetes.niddk.nih.gov/dm/pubs/insulinresistance/>. NIH Publication No. 09-4893; 2008.
6. Effect of intensive blood-glucose control with Metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, *Lancet* 1998;352(9131):854-865.
7. Yamasaki, Y., Kawamori, R., Wasada, T., Sato, A., Omori, Y., Eguchi, H., Tominaga, M., Sasaki, H., Ikeda, M., Kubota, M., Ishida, Y., Hozumi, T., Baba, S., Uehara, M., Shichiri, M., and Kaneko, T. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan, *Tohoku J Exp Med* 1997;183: 173-183.
8. Goldstein, B. J. Rosiglitazone, *Int J Clin Pract* 2000;54(5):333-337.
9. Bunck, M. C., Diamant, M., Corner, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M. R., Smith, U., Yki-Jarvinen, H., and Heine, R. J. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in Metformin-treated type 2 diabetic patients: a randomized, controlled trial, *Diabetes Care* 2009;32(5):762-768.

Glucolin-9 Human Study (2 Nov.2015)

Table 1. Blood Chemistry

	Glucolin-9	Placebo	P-Value <sup>1</sup>
<b>HbA1c (%), Mean±SD (CV%)</b>			
Baseline	7.7±0.5 (6.5)	7.7±0.5 (6.4)	0.93
Day 90	4.7±0.3 (6.2)	8±0.6 (7.2)	<0.001
Change <sup>2</sup>	-3±0.5	0.3±0.4	<0.001
Proportion Achieving HbA1c > 7%	100%	6%	
Proportion Achieving HbA1c ≥ 6%	100%	0%	
Proportion Achieving HbA1c ≥ 5%	100%	0%	
Proportion Achieving HbA1c ≥ 4.5%	32%	0%	
<b>FBG (ng/dL), Mean±SD (CV%)</b>			
Baseline	196.6±17.5 (8.9)	196.9±17.4 (8.8)	0.93
Day 90	89.4±9.2 (10.3)	205.2±20.2 (9.9)	<0.001
Change <sup>2</sup>	-107.2±14.5	8.3±14.8	<0.001
<b>Glucose Challenge Test (ng/dL), Mean±SD (CV%)</b>			
30 Minutes	110.1±24.1 (21.9)	205.1±18.5 (9)	<0.001
60 Minutes	110±23 (20.9)	221.9±14.6 (6.6)	<0.001
90 Minutes	109.5±23.3 (21.3)	225.8±12.6 (5.6)	<0.001

<sup>1</sup>F-Test for treatment on baseline; F Test for treatment based on a repeated measures ANOVA in terms of treatment, time and treatment by time and an AR(1) correlation structure otherwise (treatment by time interaction: p-value < 0.001).

<sup>2</sup>Change defined as the value at Day 90 minus the value at Baseline.

Glucolin-9 Human Study (2 Nov.2015)

Table 2. Blood Chemistry

	Glucolin-9	Placebo	P-Value <sup>1</sup>
<b>Body Weight (lbs), Mean±SD (CV%)</b>			
Baseline	211.4±54.7 (25.9)	211.6±53.6 (25.3)	0.99
Day 90	202.1±54 (26.7)	211.6±52.8 (25)	0.31
Change <sup>2</sup>	-9.3±3.1	0±2.9	<0.001
<b>Triglycerides (mM), Mean±SD (CV%)</b>			
Baseline	255.2±48.1 (18.8)	254.5±46.5 (18.3)	0.95
Day 90	203.2±42.4 (20.9)	271.3±48.3 (17.8)	<0.001
Change <sup>2</sup>	-52±23.7	16.8±28.6	<0.001
<b>LDL (µg/µL), Mean±SD (CV%)</b>			
Baseline	230.7±106.9 (46.3)	193.2±87.2 (45.1)	0.01
Day 90	151.7±33.5 (22.1)	154.4±30.3 (19.7)	0.86
Change <sup>2</sup>	-79±120.8	-38.8±94.9	0.11
<b>HDL (µg/µL), Mean±SD (CV%)</b>			
Baseline	56.8±29.8 (52.5)	57.3±29.8 (52.1)	0.93
Day 90	47.7±9.3 (19.4)	52.6±10.5 (19.9)	0.28
Change <sup>2</sup>	-9±33.6	-4.7±35	0.45

<sup>1</sup>F-Test for treatment on baseline; F Test for treatment based on a repeated measures ANOVA in terms of treatment, time and treatment by time and an AR(1) correlation structure otherwise (treatment by time interaction: p-value < 0.001).

<sup>2</sup>Change defined as the value at Day 90 minus the value at Baseline.

Glucolin-9 Human Study (2 Nov.2015)

Table 3. Blood Chemistry

	Glucolin-9	Placebo	P-Value <sup>1</sup>
<b>Total Cholesterol (µg/µL), Mean±SD (CV%)</b>			
Baseline	338.5±96.9 (28.6)	301.3±89.4 (29.7)	0.01
Day 90	240±32.8 (13.7)	261.2±29.2 (11.2)	0.13
Change <sup>2</sup>	-98.5±110	-40.1±99.6	0.004
<b>Total Cholesterol/HDL, Mean±SD</b>			
Baseline	8.5±5.9 (69.6)	7.2±5.1 (71.6)	0.1
Day 90	5.3±1.5 (28.4)	5.1±1.1 (20.4)	0.88
<b>LDL/HDL, Mean±SD</b>			
Change <sup>2</sup>	6.2±5.2	4.9±4.3	0.06
Baseline	3.4±1.3 (38.5)	3.1±0.9 (28.2)	0.65
<b>Blood Pressure (SBP/DBP; mm Hg), Mean±SD (CV%)</b>			
Baseline	75.2/171.3±9.9/19.9 (13.2/11.6)	76/155.2±8.7/25.1 (11.4/16.2)	<0.001/0.55
Day 90	70.3/142.9±3.2/14.6 (4.5/10.2)	76.6/155.2±5.2/18.9 (6.7/12.2)	0.003/<0.001
Change <sup>2</sup>	-28.4/-4.9±17.1/9	0/0.7±10.5/6.5	<0.001/<0.001

<sup>1</sup>F-Test for treatment on baseline; F Test for treatment based on a repeated measures ANOVA in terms of treatment, time and treatment by time and an AR(1) correlation structure otherwise (treatment by time interaction: p-value < 0.001).

<sup>2</sup>Change defined as the value at Day 90 minus the value at Baseline.